Literature DB >> 31637480

The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.

Hans Dieter Nischalke1, Philipp Lutz2, Eva Bartok3, Benjamin Krämer2, Bettina Langhans2, Regina Frizler2, Thomas Berg4, Jochen Hampe5, Stephan Buch5, Christian Datz6, Felix Stickel7, Gunther Hartmann3, Christian P Strassburg2, Jacob Nattermann2, Ulrich Spengler2.   

Abstract

The I148M variant of the Patatin-like phospholipase domain-containing 3 (PNPLA3) protein is associated with an increased risk for liver inflammation and hepatocellular carcinoma (HCC), but the underlying mechanism is unknown. We hypothesized that enhanced CXC chemokine secretion mediates hepatic inflammation that accelerates development of HCC. Expandable primary human (upcyte®) hepatocytes and human PLC/PRF/5 hepatoma cells were lentivirally transduced with both PNPLA3 I148M variants and stimulated with lipids. Cytokine levels in culture supernatant and patient sera (n = 80) were analyzed by ELISA. Supernatants were assessed in transmigration experiments, tube formation, and proliferation assays. In vitro, lipid stimulation of transduced hepatocytes dose-dependently induced the production of interleukin-8 and CXCL1 in hepatocytes carrying the PNPLA3 148M variant. In line, sera from PNPLA3 148M-positive patients with alcoholic liver cirrhosis contained higher levels of interleukin-8 and CXCL1 than patients with wild-type PNPLA3. Supernatants from lipid-stimulated hepatocytes with the PNPLA3 148M variant induced enhanced migration of white blood cells, angiogenesis, and cell proliferation in comparison with supernatants from wild-type hepatocytes via CXC receptors 1 and 2. Increased production of interleukin-8 and CXCL1 by hepatocytes carrying the PNPLA3 148M variant contributes to a pro-inflammatory and tumorigenic milieu in patients with alcoholic liver disease. KEY MESSAGES: The PNPLA3 148M variant is associated with cirrhosis and hepatocellular carcinoma. Lipid stimulation of hepatocytes with this variant induces IL-8 and CXCL1. Supernatants from hepatocytes with this variant promote migration and angiogenesis. Sera from patients with this variant contained enhanced levels of IL-8 and CXCL1. The PNPLA3 148M variant contributes to a tumorigenic milieu via IL-8 and CXCL1.

Entities:  

Keywords:  CXCL1; HCC; IL-8; PNPLA3 148M; alcoholic liver disease; cirrhosis; rs738409

Mesh:

Substances:

Year:  2019        PMID: 31637480     DOI: 10.1007/s00109-019-01836-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  49 in total

1.  Variant in PNPLA3 is associated with alcoholic liver disease.

Authors:  Chao Tian; Renee P Stokowski; David Kershenobich; Dennis G Ballinger; David A Hinds
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

Review 2.  Roles for chemokines in liver disease.

Authors:  Fabio Marra; Frank Tacke
Journal:  Gastroenterology       Date:  2014-07-25       Impact factor: 22.682

3.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.

Authors:  Stephan Buch; Felix Stickel; Eric Trépo; Michael Way; Alexander Herrmann; Hans Dieter Nischalke; Mario Brosch; Jonas Rosendahl; Thomas Berg; Monika Ridinger; Marcella Rietschel; Andrew McQuillin; Josef Frank; Falk Kiefer; Stefan Schreiber; Wolfgang Lieb; Michael Soyka; Nasser Semmo; Elmar Aigner; Christian Datz; Renate Schmelz; Stefan Brückner; Sebastian Zeissig; Anna-Magdalena Stephan; Norbert Wodarz; Jacques Devière; Nicolas Clumeck; Christoph Sarrazin; Frank Lammert; Thierry Gustot; Pierre Deltenre; Henry Völzke; Markus M Lerch; Julia Mayerle; Florian Eyer; Clemens Schafmayer; Sven Cichon; Markus M Nöthen; Michael Nothnagel; David Ellinghaus; Klaus Huse; Andre Franke; Steffen Zopf; Claus Hellerbrand; Christophe Moreno; Denis Franchimont; Marsha Y Morgan; Jochen Hampe
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

4.  Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.

Authors:  Felix Stickel; Stephan Buch; Hans Dieter Nischalke; Karl Heinz Weiss; Daniel Gotthardt; Janett Fischer; Jonas Rosendahl; Astrid Marot; Mona Elamly; Markus Casper; Frank Lammert; Andrew McQuillin; Steffen Zopf; Ulrich Spengler; Silke Marhenke; Martha M Kirstein; Arndt Vogel; Florian Eyer; Johann von Felden; Henning Wege; Thorsten Buch; Clemens Schafmayer; Felix Braun; Pierre Deltenre; Thomas Berg; Marsha Y Morgan; Jochen Hampe
Journal:  Am J Gastroenterol       Date:  2018-03-13       Impact factor: 10.864

Review 5.  Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.

Authors:  Chi Ma; Qianfei Zhang; Tim F Greten
Journal:  FEBS J       Date:  2017-09-15       Impact factor: 5.542

6.  Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.

Authors:  Manal M Hassan; Ahmed Kaseb; Carol J Etzel; Hashem El-Serag; Margaret R Spitz; Ping Chang; Katherine S Hale; Mei Liu; Asif Rashid; Mohamed Shama; James L Abbruzzese; Evelyne M Loyer; Harmeet Kaur; Hesham M Hassabo; Jean-Nicolas Vauthey; Curtis J Wray; Basmah S Hassan; Yehuda Z Patt; Ernest Hawk; Khalid M Soliman; Donghui Li
Journal:  Mol Carcinog       Date:  2013-06-15       Impact factor: 4.784

7.  Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis.

Authors:  Henning W Zimmermann; Sebastian Seidler; Nikolaus Gassler; Jacob Nattermann; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

8.  Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Zhongwei Cao; Biao Fu; Biao Deng; Yue Zeng; Xinjian Wan; Lei Qu
Journal:  Cancer Cell Int       Date:  2014-09-24       Impact factor: 5.722

9.  Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.

Authors:  Daniel Lindén; Andrea Ahnmark; Piero Pingitore; Ester Ciociola; Ingela Ahlstedt; Anne-Christine Andréasson; Kavitha Sasidharan; Katja Madeyski-Bengtson; Magdalena Zurek; Rosellina M Mancina; Anna Lindblom; Mikael Bjursell; Gerhard Böttcher; Marcus Ståhlman; Mohammad Bohlooly-Y; William G Haynes; Björn Carlsson; Mark Graham; Richard Lee; Sue Murray; Luca Valenti; Sanjay Bhanot; Peter Åkerblad; Stefano Romeo
Journal:  Mol Metab       Date:  2019-02-05       Impact factor: 7.422

10.  Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a.

Authors:  Xiao Cui; Zhao Li; Jie Gao; Peng-Ji Gao; Yan-Bing Ni; Ji-Ye Zhu
Journal:  Oncotarget       Date:  2016-10-04
View more
  1 in total

1.  Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.

Authors:  Francesca V Bruschi; Matteo Tardelli; Merima Herac; Thierry Claudel; Michael Trauner
Journal:  Liver Int       Date:  2020-03-01       Impact factor: 5.828

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.